Bristol Myers Squibb Company (NYSE:BMY) Shares Purchased by Natixis Advisors LLC

Key Points

• Natixis Advisors LLC increased its stake in Bristol Myers Squibb by 16.3% during the first quarter, holding a total of 791,667 shares worth approximately $48.28 million.
• Bristol Myers Squibb reported an earnings per share (EPS) of $1.46 for the last quarter, exceeding analysts' expectations of $1.07 and achieving a revenue of $12.27 billion.
• The company announced a quarterly dividend of $0.62 to be paid on August 1st, representing a 5.7% yield and a payout ratio of 92.88%.

Natixis Advisors LLC boosted its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 16.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 791,667 shares of the biopharmaceutical company's stock after purchasing an additional 110,826 shares during the quarter. Natixis Advisors LLC's holdings in Bristol Myers Squibb were worth $48,284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of BMY. Pinney & Scofield Inc. bought a new position in Bristol Myers Squibb in the 4th quarter worth $25,000. Park Square Financial Group LLC purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at about $26,000. Transce3nd LLC purchased a new stake in Bristol Myers Squibb in the fourth quarter worth about $28,000. Global Wealth Strategies & Associates boosted its position in Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 275 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Bristol Myers Squibb during the 1st quarter worth approximately $31,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Price Performance

Shares of BMY traded up $0.94 during mid-day trading on Friday, hitting $44.25. The company's stock had a trading volume of 18,626,740 shares, compared to its average volume of 12,693,902. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. The firm has a 50-day simple moving average of $47.51 and a 200 day simple moving average of $52.26. The firm has a market capitalization of $90.05 billion, a P/E ratio of 17.84, a P/E/G ratio of 2.35 and a beta of 0.36. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. The firm had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.60% and a net margin of 10.58%. Bristol Myers Squibb's revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.07 earnings per share. Analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.6%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb's payout ratio is 100.00%.

Analyst Ratings Changes

A number of equities analysts have weighed in on BMY shares. Jefferies Financial Group decreased their target price on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Argus upgraded Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 price objective (down from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Finally, UBS Group dropped their target price on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $57.33.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.